Transformative advances in synthetic immunotherapy: mechanistic insights and therapeutic innovations for autoimmune diseases
Article Sidebar
Main Article Content
Abstract
Synthetic immunotherapy represents a transformative advancement in the treatment of autoimmune diseases, by integrating synthetic biology, gene editing, nanotechnology, and artificial intelligence to develop highly targeted and effective therapeutic strategies. Autoimmune diseases are characterized by a breakdown in immune tolerance, resulting in chronic inflammation and progressive tissue damage driven by autoreactive lymphocytes, cytokine dysregulation, and genetic predispositions. Although conventional therapies such as corticosteroids and biologics have improved disease management, they are frequently associated with adverse effects and limited long-term efficacy.
This review explores the latest innovations in synthetic immunotherapy, including CRISPR/Cas9-mediated genome editing, chimeric antigen receptor (CAR) T-cell therapies, synthetic antigen-presenting cells (APCs), and nanotechnology-based drug delivery systems. The integration of multi-omics technologies and artificial intelligence further enhances the precision and personalization of these therapies by identifying biomarker and optimizing therapeutic responses. Despite these advances, challenges such as off-target effects, systemic toxicity, manufacturing scalability, and ethical concerns remain significant barriers to clinical translation. Regulatory considerations and economic factors further complicate widespread adoption and accessibility.
We critically assess the current landscape of synthetic immunotherapy, highlighting its transformative potential while addressing key obstacles that must be overcome for successful clinical implementation. Future research directions emphasize the need for improved safety mechanisms, regulatory frameworks, and interdisciplinary collaboration to maximize therapeutic impact. As synthetic biology continues to evolve, these innovations hold the promise of revolutionizing autoimmune disease treatment through precision-engineered interventions, that enable safer, more effective, and personalized therapeutic solutions.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ประกาศเกี่ยวกับลิขสิทธิ์
บทความที่ลงพิมพ์ในวารสารสถาบันราชประชาสมาสัย ถือว่าเป็นผลงานทางวิชาการหรือการวิจัย และวิเคราะห์ตลอดจนเป็นความเห็นส่วนตัวของผู้นิพนธ์ ไม่ใช่ความเห็นของกรมควบคุมโรค ประเทศไทย หรือกองบรรณาธิการแต่ประการใด ผู้นิพนธ์จำต้องรับผิดชอบต่อบทความของตน
นโยบายส่วนบุคคล
ชื่อและที่อยู่อีเมลที่ระบุในวารสารสถาบันราชประชาสมาสัย จะถูกใช้เพื่อวัตถุประสงค์ตามที่ระบุไว้ ในวารสารเท่านั้น และจะไม่ถูกนำไปใช้สำหรับวัตถุประสงค์อื่น หรือต่อบุคคลอื่นใด
References
Elkoshi Z. Autoimmune Diseases Refractory to Corticosteroids and Immunosuppressants. Frontiers in Immunology [Internet]. 2024 [cited 2025 Mar 25];15:1447337. Available from: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1447337/full
Adytia GJ, Sutanto H, Pratiwi L, Fetarayani D. Advances in Synthetic Immunology for Targeted Treatment of Systemic Autoimmune Diseases: Opportunities, Challenges, and Future Directions. Immuno [Internet]. 2025 [cited 2025 Mar 25];5(1):6. Available from: https://www. mdpi.com/2673-5601/5/1/6
Lee MH, Shin JI, Yang JW, Lee KH, Cha DH, Hong JB, et al. Genome Editing Using CRISPR-Cas9 and Autoimmune Diseases: a Comprehensive Review. International Journal of Molecular Sciences [Internet]. 2022 [cited 2025 Mar 25];23(3):1337. Available from: https://www.mdpi.com/1422-0067/23/3/1337
Park H, Mugundu GM, Singh AP. Mechanistic Evaluation of Anti‐CD19 CAR‐T Cell Therapy Repurposed in Systemic Lupus Erythematosus Using a Quantitative Systems Pharmacology Model. Clinical and Translational Science [Internet]. 2025 [cited 2025 Mar 25];18(2):e70146. Available from: https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.70146
Zhou J, Lei B, Shi F, Luo X, Wu K, Xu Y, et al. CAR T-cell Therapy for Systemic Lupus erythematosus: Current Status and Future Perspectives. Frontiers in Immunology [Internet]. 2024 [cited 2025 Mar 25];15:1476859. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11694027/
Reddy NR, Maachi H, Xiao Y, Simic MS, Yu W, Tonai Y, et al. Engineering Synthetic Suppressor T Cells That Execute Locally Targeted Immunoprotective Programs. Science [Internet]. 2024 [cited 2025 Mar 25];386(6726):eadl4793. Available from: https://www.science.org/doi/10.1126/science.adl4793
Menter A, Krueger GG, Paek SY, Kivelevitch D, Adamopoulos IE, Langley RG. Interleukin-17 and Interleukin-23: a Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities. Dermatology and Therapy [Internet]. 2021 [cited 2025 Mar 25];11(2):385–400. Available from: https://link.springer.com/article/10.1007/s13555-021-00483-2
Maeyama A, Kondo M, Harada H, Shono E, Nagamine R, Tsuru T, et al. Efficacy and Safety of Baricitinib in Rheumatoid Arthritis Patients with Moderate Renal impairment: a Multicenter Propensity Score Matching Study. BMC Rheumatology [Internet]. 2024 [cited 2025 Mar 25];8(1):69. Available from: https://doi.org/10.1186/s41927-024-00446-y
O’Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus Kinase Inhibitors in Autoimmune Diseases. Annals of the Rheumatic Diseases [Internet]. 2013 [cited 2025 Mar 25];72(02): 111-5. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC3616338/
Xu Y, Chen C, Guo Y, Hu S, Sun Z. Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy. Frontiers in Immunology [Internet]. 2022 [cited 2025 Mar 25];13:848327. Available from: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.848327/full
Tang X, Zhang Y, Zhang H, Zhang N, Dai Z, Cheng Q, et al. Single-Cell Sequencing: High-Resolution Analysis of Cellular Heterogeneity in Autoimmune Diseases. Clinical Reviews in Allergy & Immunology [Internet]. 2024 [cited 2025 Mar 25];66(3):376-400. Available from: https://link.springer.com/article/10.1007/s12016-024-09001-6
Turtle CJ, Riddell SR. Artificial Antigen-Presenting Cells for Use in Adoptive Immunotherapy. The Cancer Journal [Internet]. 2010 [cited 2025 Mar 25];16(4):374–81. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC2929753/
Ferreira LMR, Muller YD, Bluestone JA, Tang Q. Next-generation Regulatory T Cell Therapy. Nature Reviews Drug Discovery [Internet]. 2019 [cited 2025 Mar 25];18(10):749–69. Available from: https://www.nature.com/articles/s41573-019-0041-4
Lim S, Park J, Shim MK, Um W, Yoon HY, Ryu JH, et al. Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy. Theranostics. 2019;9(25):7906–23.
Sriwidodo, Umar AbdK, Wathoni N, Zothantluanga JH, Das S, Luckanagul JA. Liposome-polymer Complex for Drug Delivery System and Vaccine Stabilization. Heliyon [Internet]. 2022 [cited 2025 Mar 25];8(2):e08934. Available from: https://doi.org/10.1016/j.heliyon.2022.e08934
Peng L, Jin X, Li B, Zeng X, Liao B, Jin T, et al. Integrating single-cell RNA Sequencing with Spatial Transcriptomics Reveals Immune Landscape for Interstitial Cystitis. Signal Transduction and Targeted Therapy [Internet]. 2022 [cited 2025 Mar 25];7(1):161. Available from: https://www.nature.com/articles/s41392-022-00962-8.pdf
Galluzzo M, Vellucci L, Marcelli L, Paganini C, Bianchi L, Talamonti M. Deucravacitinib, a Selective Tyrosine Kinase 2 inhibitor, for the Treatment of moderate-to-severe Plaque Psoriasis. Expert Opinion on Pharmacotherapy [Internet]. 2023 [cited 2025 Mar 25];24(9):981–8. Available from: https://www.tandfonline.com/doi/full/10.1080/14656566.2023.2211764
Topol EJ. High-performance medicine: the Convergence of Human and Artificial Intelligence. Nature Medicine [Internet]. 2019 [cited 2025 Mar 25];25(1):44–56. Available from: https://www.nature.com/articles/s41591-018-0300-7
Wittmann M, Helliwell PS. Phosphodiesterase 4 Inhibition in the Treatment of Psoriasis, Psoriatic Arthritis and Other Chronic Inflammatory Diseases. Dermatology and Therapy [Internet]. 2013 [cited 2025 Mar 25];3(1):1–15. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680635/
Suhag D. Regulatory and Ethical Considerations. In: Handbook of Biomaterials for Medical Applications, Volume 2 [Internet]. Singapore. Springer Nature Singapore; 2024 [cited 2025 Mar 25]. 355–72 p. Available from: https://link.springer.com/chapter/10.1007/978-981-97-5906-4_11
Li J, Chen P, Ma W. The next Frontier in immunotherapy: Potential and Challenges of CAR-macrophages. Experimental Hematology and Oncology [Internet]. 2024 [cited 2025 Mar 25];13(1):76. Available from: https://ehoonline.biomedcentral.com/articles/10.1186/s40164-024-00549-9
Chang ZL, Chen YY. CARs: Synthetic Immunoreceptors for Cancer Therapy and beyond. Trends in Molecular Medicine [Internet]. 2017 [cited 2025 Mar 25];23(5):430–50. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC5423782/
Goswami TK, Singh M, Dhawan M, Mitra S, Emran TB, Rabaan AA, et al. Regulatory T Cells (Tregs) and Their Therapeutic Potential against Autoimmune Disorders - Advances and Challenges. Human Vaccines & Immunotherapeutics [Internet]. 2022 [cited 2025 Mar 25];18(1):2035117. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9009914/
Gaj T, Gersbach CA, Barbas CF. ZFN, TALEN, and CRISPR/Cas-based Methods for Genome Engineering. Trends in Biotechnology [Internet]. 2013 [cited 2025 Mar 25];31(7):397–405. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694601/
Garcia JM, Burnett CE, Roybal KT. Toward the Clinical Development of Synthetic Immunity to Cancer. Immunological Reviews [Internet]. 2023 [cited 2025 Mar 25];20(1):83–99. Available from: https://onlinelibrary.wiley.com/doi/10.1111/imr.13245
Lin H, Li C, Zhang W, Wu B, Wang Y, Wang S, et al. Synthetic Cells and Molecules in Cellular Immunotherapy. International Journal of Biological Sciences [Internet]. 2024 [cited 2025 Apr 2];20(8):2833–59. Available from: https://www.ijbs.com/v20p2833.htm
Figdor CG, Mandal S, Hammink R, Eggermont L, Weiden J, Voerman D, et al. Abstract IA29: Towards Synthetic Immune Cells for Cancer Immunotherapy. Cancer Immunology Research [Internet]. 2016 [cited 2025 Mar 25];4(1_Supplement):IA29. Available from: https://aacrjournals.org/cancerimmunolres/article/4/1_Supplement/IA29/468245/Abstract-IA29-Towards-synthetic-immune-cells-for
Shin HS, Kim S, Jin SM, Yoo YJ, Heo JH, Lim YT. Molecular Masking of Synthetic Immunomodulator Evokes Antitumor Immunity with Reduced Immune Tolerance and Systemic Toxicity by Temporal Activity Recovery and Sustained Stimulation. Advanced Materials [Internet]. 2023 [cited 2025 Mar 25];36(9):e2309039. Available from: https://advanced.onlinelibrary.wiley.com/doi/abs/10.1002/adma.202309039
Shim MK, Yang S, Sun IC, Kim K. Tumor-activated carrier-free Prodrug Nanoparticles for Targeted Cancer Immunotherapy: Preclinical Evidence for Safe and Effective Drug Delivery. Advanced Drug Delivery Reviews [Internet]. 2022 [cited 2025 Mar 25];183:114177. Available from: https://pubmed.ncbi.nlm.nih.gov/35245568/
